Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Clinical activity after fingolimod cessation: disease reactivation or rebound?.Eur. J. Neurol. 2018; 25: 1270-1275
- Disease exacerbation after the cessation of fingolimod treatment in japanese patients with Multiple Sclerosis.Intern. Med. 2018; 57: 2647-2655
- Disease reactivation after fingolimod discontinuation in pregnant Multiple Sclerosis patients.Neurotherapeutics. 2021; 18 (Epub 2021 Sep 7): 2598-2607https://doi.org/10.1007/s13311-021-01106-6
- Factors associated with fingolimod rebound: a single center real-life experience.Mult. Scler. Relat. Dis. 2021; 56103278
- Factors predictive of severe Multiple Sclerosis disease reactivation after fingolimod cessation.Neurologist. 2018; 23: 12-16
- Rebound of Multiple Sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors.Mult. Scler. Relat. Dis. 2020; 38101483
- Rebound syndrome in patients with Multiple Sclerosis after cessation of fingolimod treatment.JAMA Neurol. 2016; 73: 790
- A comparison of Multiple Sclerosis disease activity after discontinuation of fingolimod and placebo.Mult. Scler. J. Exp. Transl. Clin. 2017; 32055217317730096
- Natalizumab, fingolimod, and dimethyl fumarate use and pregnancy-related relapse and disability in women with Multiple Sclerosis.Neurology. 2021; 96: e2989-e3002
- Relapse occurrence in women with Multiple Sclerosis during pregnancy in the new treatment era.Neurology. 2018; 90: e840-e846